/PRNewswire/ -- GeneLink BioSciences, Inc. (OTC Bulletin Board: GNLK,
) today announced the launch of HelixLife, (
), a private label distribution partnership serving the healthcare and wellness industries.
, GeneLink CEO, stated, "HelixLife gives GeneLink reach into new areas of the rapidly expanding personalized wellness markets that previously have not been available to us. The HelixLife team is very experienced and will expand the visibility and healthcare market penetration of our 'Powered by GeneLink' technologies and our unique genetically-guided nutritional and skin care products."
, HelixLife CEO added, "We are excited to showcase GeneLink's 16 years of incredible DNA research and product development with the HelixLife product line of anti-aging nutritional supplements and skin serums, youth supplements and anti-acne products. We look forward to working together to optimize our customer's health, appearance and well being."
The HelixLife product line includes:
™ custom DNA nutritional adult supplements and anti-aging skin serum formulated and manufactured to each customer's specific genetic profile,
™ DNA nutritional and skin assessment test,
™ full-spectrum adult foundational supplements,
™ nutritional supplements custom-designed for youth ages 11-17,
™ natural and organic anti-aging skin serum,
™ non-chemical based anti-acne skin serum, and
™ chocolate-based energy chews, a healthy alternative to energy drinks
HelixLife products are manufactured in the
from the highest quality, freshest ingredients, and are shipped directly from production to customer, not warehouse-stored. For more information, go to
About GeneLink BioSciences, Inc.
GeneLink is a genomics, biotechnology, and wellness company engaged in genetic test development, product development, and manufacturing of personalized wellness products. GeneLink's patented and proprietary technologies include genetic assessments focused on the delivery of personally customized and manufactured nutritional supplements and skin care products for health, beauty and wellness applications. For additional information, please visit
This release contains certain forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in the press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement. GeneLink disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future developments or otherwise.
SOURCE GeneLink BioSciences, Inc.